
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is supported by a strengthening launch pipeline and resilient core demand, with AMP-007 recently approved by the FDA in February 2026 and launched in April 2026, backed by 180 days of generic exclusivity that could make it a $30MM-$40MM sales opportunity. Management’s guidance for 2027 launches of AMP-018 and AMP-004 adds visible future catalysts, while AMP-110 provides longer-term upside in a two-player ACTH category with brisk volume growth. Even with Baqsimi expectations adjusted lower, the company still maintained 2026 high-single digit top-line growth, helped by solid 1Q26 sales in Primatene at $29.8M and epinephrine at $19.2MM, reinforcing a positive fundamental outlook.
Bears say
Amphastar Pharma is under pressure because its flagship Baqsimi franchise is facing persistent pricing erosion from higher rebates, 340B pharmacy discounts, and a less favorable channel mix, with 2Q26 sales of $45.5M down from $46.7M in 2Q25 despite 17% prescription growth. Its core generics business is also weakening, as injectable glucagon fell about 42% in 2Q26 and 56% in 1Q26 after Viatris entered the market in December 2024, while epinephrine growth has been modest and partly offset by supplier shortages. Although revenue reached $183.9M in 2Q26 and non-GAAP EPS beat estimates at $0.91, the pipeline remains too uncertain, with limited visibility into when Phase I ACTH or other shots-on-goal can support durable top-line and EBITDA growth.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Amphastar Pharma (AMPH) Forecast
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares